Top

03-11-2024 | Edema | Review article

Renal involvement in TAFRO syndrome: a review

Authors: Yoshifumi Ubara, Naoki Sawa

Published in: Clinical and Experimental Nephrology

Abstract

Renal involvement in TAFRO syndrome is characterized clinically by general edema with ascites and pleural effusions and a rapidly progressive decline in renal function, with urinary protein levels of usually less than 1 g/day. The histologic features of the kidneys can be described as glomerular microangiopathy characterized by mesangiolysis or mesangial loosening, endothelial cell proliferation, edematous opening in the subendothelial space, and glomerular basement membrane (GBM) doubling due to newly formed basement membrane. Findings such as rupture of the GBM, foot-process effacement or fusion, and epithelial cell loss are rare, and thrombus formation is difficult to identify in the glomerulus. Furthermore, immunodeposits are not seen on immunofluorescence staining or electron microscopy. Unlike adults, in addition to the glomerular lesions described above, adolescents appear to show intimal proliferation of the arterioles and interlobular arteries to the vascular poles and occlusion of the vascular lumen.

Takai K, Nikkuni K, Momoi A, Nagai K, Igarashi N, Saeki T. Thrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly: a clinical report of five cases. J Clin Exp Hematop. 2013;53:63–8.CrossRefPubMed

Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, Masunari T, Yoshida I, Moro H, Nikkuni K, Takai K, Matsue K, Kurosawa M, Hagihara M, Saito A, Okamoto M, Yokota K, Hiraiwa S, Nakamura N, Nakao S, Yoshino T, Sato Y. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicenteric Castleman disease. Am J Hematol. 2016;91:220–6.CrossRefPubMed

Masaki Y, Kawabata H, Takai K, Kojima M, Tsukamoto N, Ishigaki Y, Kurose N, Ide M, Murakami J, Nara K, Yamamoto H, Ozawa Y, Takahashi H, Miura K, Miyauchi T, Yoshida S, Momoi A, Awano N, Ikushima S, Ohta Y, Furuta N, Fujimoto S, Kawanami H, Sakai T, Kawanami T, Fujita Y, Fukushima T, Nakamura S, Kinoshita T, Aoki S. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016;103:686–92.CrossRefPubMed

Noda-Narita S, Sumida K, Sekine A, Hoshino J, Mise K, Suwabe T, Hayami N, Yamanouchi M, Ueno T, Mizuno H, Kawada M, Hiramatsu R, Hasegawa E, Sawa N, Takaichi K, Ohashi K, Fujii T, Ubara Y. TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report. CEN Case Rep. 2018;7(1):162–8.CrossRefPubMedPubMedCentral

Mizuno H, Sekine A, Oguro M, Oshima Y, Kawada M, Sumida K, Yamanouchi M, Hayami N, Suwabe T, Hiramatsu R, Hasegawa E, Hoshino J, Sawa N, Fujii T, Takaichi K, Ohashi K, Ubara Y. Renal histology in a patient with TAFRO syndrome: a case report. Hum Pathol. 2018;82:258–63.CrossRefPubMed

Nakayama Y, Mizuno H, Sawa N, Suwabe T, Yamanouchi M, Ikuma D, Hasegawa E, Hoshino J, Sekine A, Oba Y, Kono K, Kinowaki K, Ohashi K, Suzuki K, Sato Y, Shimizu A, Yamaguchi Y, Ubara Y. Adolescent-onset TAFRO syndrome with malignant nephrosclerosis-like lesions. Intern Med. 2023;62(15):2223–9.CrossRefPubMed

Mizuno H, Sawa N, Watanabe S, Ikuma D, Sekine A, Kawada M, Yamanouchi M, Hasegawa E, Suwabe T, Hoshino J, Takaichi K, Kinowaki K, Fujii T, Ohashi K, Nagata M, Yamaguchi Y, Ubara Y. The clinical and histopathological feature of renal manifestation of TAFRO syndrome. Kidney Int Rep. 2020;5(8):1172–9.CrossRefPubMedPubMedCentral

Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129–36.CrossRefPubMedPubMedCentral

Ubara Y, Kawaguchi T, Nagasawa T, Miura K, Katsuno T, Morikawa T, Ishikawa E, Ogura M, Matsumura H, Kurayama R, Matsumoto S, Marui Y, Hara S, Maruyama S, Narita I, Okada H, Tsuruya K, Committee of Practical Guide for Kidney Biopsy 2020. Kidney biopsy guidebook 2020 in Japan. Clin Exp Nephrol. 2021;25(4):325–64.CrossRefPubMedPubMedCentral

10.

Sakai T, Lemley KV, Hackenthal E, Nagata M, Nobiling R, Kriz W. Changes in glomerular structure following acute mesangial failure in the isolated perfused kidney. Kidney Int. 1992;41(3):533–41.CrossRefPubMed

11.

van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115–24.CrossRefPubMedPubMedCentral

12.

Imafuku A, Suwabe T, Hasegawa E, Mise K, Sumida K, Hiramatsu R, Yamanouchi M, Hayami N, Hoshino J, Sawa N, Oohashi K, Fujii T, Okubo M, Takaichi K, Oga T, Ubara Y. Castleman’s disease accompanied by hypolipidemic cerebral hemorrhage and nephrosclerosis. Intern Med. 2013;52(14):1611–6.CrossRefPubMed

13.

Ogita M, Hoshino J, Sogawa Y, Sawa N, Katori H, Takemoto F, Ubara Y, Hara S, Miyakoshi S, Takaichi K. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Clin Nephrol. 2007;68(3):171–6.CrossRefPubMed

14.

Matsunami M, Ubara Y, Sumida K, Oshima Y, Oguro M, Kinoshita K, Tanaka K, Nakamura Y, Kinowaki K, Ohashi K, Fujii T, Igawa T, Sato Y, Ishii Y. The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome. BMC Nephrol. 2018;19(1):263.CrossRefPubMedPubMedCentral

15.

Iijima T, Hoshino J, Suwabe T, Sumida K, Mise K, Kawada M, Ueno T, Hamanoue S, Hayami N, Hiramatsu R, Sawa N, Takaichi K, Ubara Y. Tocilizumab for AA amyloidosis after treatment of multicentric castleman disease with steroids, chemotherapy and rituximab for over 20 years. Intern Med. 2015;54(24):3215–9.CrossRefPubMed

16.

Tosaki T, Okabe M, Suzuki T, Shimizu A, Koike K, Tsuboi N, Kawamura T, Ohashi R, Yano S, Yokoo T. Membranous nephropathy with thrombotic microangiopathy-like lesions successfully treated with tocilizumab in a patient with idiopathic multicentric Castleman disease. CEN Case Rep. 2021;10(2):265–72.CrossRefPubMedPubMedCentral

17.

Yoshimura Y, Mizuno H, Ikuma D, Yamanouchi M, Sekine A, Suwabe T, Oba Y, Kurihara S, Sugimoto H, Inoue N, Yoshimoto M, Tanimizu H, Tsunoda S, Iijima M, Kono K, Kinowaki K, Ohashi K, Takazawa Y, Hasegawa E, Ubara Y, Sawa N. Long-term clinicopathological characteristics of TAFRO syndrome and its relapse: a case series study. Clin Kidney J. 2024;17(7): sfae110.CrossRefPubMedPubMedCentral

Title: Renal involvement in TAFRO syndrome: a review
Authors: Yoshifumi Ubara
Naoki Sawa
Publication date: 03-11-2024
Publisher: Springer Nature Singapore
Keywords: Edema
Ascites
Published in: Clinical and Experimental Nephrology
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-024-02573-9

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Keynote webinar | Spotlight on adolescent vaping

Live
Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Please log in to get access to this content

Keynote series | Spotlight on menopause

Keynote webinar | Spotlight on adolescent vaping

Keynote webinar | Spotlight on modern management of frailty

A quick guide to ECGs

At a glance: The STEP trials